Sánchez-Del-Campo L - Search Results

1

Directed phenotype switching as an effective antimelanoma strategy.

Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN. Sáez-Ayala M, et al. Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. Epub 2013 Jun 20. Cancer Cell. 2013. PMID: 23792190 Free article.

2

Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate.

Sánchez-del-Campo L, Otón F, Tárraga A, Cabezas-Herrera J, Chazarra S, Rodríguez-López JN. Sánchez-del-Campo L, et al. J Med Chem. 2008 Apr 10;51(7):2018-26. doi: 10.1021/jm701346h. Epub 2008 Mar 7. J Med Chem. 2008. PMID: 18324763

3

Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

Sánchez-del-Campo L, Rodríguez-López JN. Sánchez-del-Campo L, et al. Int J Cancer. 2008 Nov 15;123(10):2446-55. doi: 10.1002/ijc.23813. Int J Cancer. 2008. PMID: 18729182 Free article.

4

The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-kappaB suppression.

Navarro-Perán E, Cabezas-Herrera J, Sánchez-Del-Campo L, García-Cánovas F, Rodríguez-López JN. Navarro-Perán E, et al. Inflamm Res. 2008 Oct;57(10):472-8. doi: 10.1007/s00011-008-8013-x. Inflamm Res. 2008. PMID: 18830563

5

Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase.

Sánchez-del-Campo L, Tárraga A, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN. Sánchez-del-Campo L, et al. Mol Pharm. 2009 May-Jun;6(3):883-94. doi: 10.1021/mp800259k. Mol Pharm. 2009. PMID: 19358568

6

The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate.

Sánchez-del-Campo L, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN. Sánchez-del-Campo L, et al. Pigment Cell Melanoma Res. 2009 Oct;22(5):588-600. doi: 10.1111/j.1755-148X.2009.00586.x. Epub 2009 Jun 2. Pigment Cell Melanoma Res. 2009. PMID: 19493312

7

Binding of natural and synthetic polyphenols to human dihydrofolate reductase.

Sánchez-Del-Campo L, Sáez-Ayala M, Chazarra S, Cabezas-Herrera J, Rodríguez-López JN. Sánchez-Del-Campo L, et al. Int J Mol Sci. 2009 Dec 18;10(12):5398-5410. doi: 10.3390/ijms10125398. Int J Mol Sci. 2009. PMID: 20054477 Free PMC article.

8

Purification and kinetic properties of human recombinant dihydrofolate reductase produced in Bombyx mori chrysalides.

Chazarra S, Aznar-Cervantes S, Sánchez-del-Campo L, Cabezas-Herrera J, Xiaofeng W, Cenis JL, Rodríguez-López JN. Chazarra S, et al. Appl Biochem Biotechnol. 2010 Nov;162(7):1834-46. doi: 10.1007/s12010-010-8961-9. Appl Biochem Biotechnol. 2010. PMID: 20393885

9

Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

Sánchez-del-Campo L, Chazarra S, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN. Sánchez-del-Campo L, et al. J Cell Biochem. 2010 Aug 15;110(6):1399-409. doi: 10.1002/jcb.22656. J Cell Biochem. 2010. PMID: 20564235

10

Comparison of a pair of synthetic tea-catechin-derived epimers: synthesis, antifolate activity, and tyrosinase-mediated activation in melanoma.

Sáez-Ayala M, Sánchez-del-Campo L, Montenegro MF, Chazarra S, Tárraga A, Cabezas-Herrera J, Rodríguez-López JN. Sáez-Ayala M, et al. ChemMedChem. 2011 Mar 7;6(3):440-9. doi: 10.1002/cmdc.201000482. Epub 2011 Feb 7. ChemMedChem. 2011. PMID: 21302360

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

29 results

Search Page